Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
10 Talazoparib Trials Near You
Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerAtezolizumab + Talazoparib for Small Cell Lung Cancer
Springfield, Ohio
This phase II trial studies whether atezolizumab in combination with talazoparib works better than atezolizumab alone as maintenance therapy for patients with SLFN11-positive extensive-stage small cell lung cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. PARPs are proteins that help repair damage to DNA, the genetic material that serves as the body's instruction book. Changes (mutations) in DNA can cause tumor cells to grow quickly and out of control, but PARP inhibitors like talazoparib may keep PARP from working, so tumor cells can't repair themselves, and they stop growing. Giving atezolizumab in combination with talazoparib may help lower the chance of extensive-stage small cell lung cancer growing and spreading compared to atezolizumab alone.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Brain Metastases, Uncontrolled Diabetes, Active Tuberculosis, Others
Must Be Taking:Platinum, Etoposide, Atezolizumab
94 Participants Needed
Targeted Therapy for Advanced Stage Cancer
Kettering, Ohio
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.
NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers).
\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*
Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress.
\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:12+
Sex:All
Key Eligibility Criteria
Disqualifiers:Primary Brain Tumors, Leptomeningeal Metastases, Others
Must Be Taking:Targeted Therapies
4200 Participants Needed
Talazoparib + Enzalutamide for Prostate Cancer
Cincinnati, Ohio
This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:Male
Key Eligibility Criteria
Disqualifiers:Cardiovascular Disease, Renal Dysfunction, Hepatic Dysfunction, Brain Metastasis, Others
Must Not Be Taking:Opioids, P-gp Inhibitors
1054 Participants Needed
Talazoparib + Chemotherapy for Acute Myeloid Leukemia
Cincinnati, Ohio
This trial is testing the safety of using talazoparib with standard chemotherapy in cancer patients. Talazoparib works by stopping cancer cells from repairing themselves, which could make chemotherapy more effective. The study aims to find the safest dose combination and see if this approach helps patients. Talazoparib is FDA approved for certain types of breast cancer that have spread and were previously treated with chemotherapy.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 21
Sex:All
Key Eligibility Criteria
Disqualifiers:Down Syndrome, APL, JMML, Others
Must Not Be Taking:Chemotherapy, Radiation, Immunotherapy, Biologics
34 Participants Needed
Talazoparib + Enzalutamide for Metastatic Prostate Cancer
Middleburg Heights, Ohio
The purpose of the study is to evaluate the safety and efficacy of talazoparib in combination with enzalutamide compared with placebo in combination with enzalutamide in participants with DDR-deficient mCSPC.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:Male
Key Eligibility Criteria
Disqualifiers:Seizure History, Brain Metastasis, Cardiovascular Disease, Others
Must Be Taking:GnRH Agonists/antagonists
599 Participants Needed
Talazoparib + Temozolomide for Small Cell Lung Cancer
Fort Wayne, Indiana
This trial studies how effective talazoparib and temozolomide are for treating patients with extensive-stage small cell lung cancer that has come back after initial chemotherapy. Talazoparib stops cancer cells from repairing their DNA, while temozolomide kills or stops the growth of these cells. The combination may work better than either drug alone.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Myelodysplastic Syndrome, Gastrointestinal Disorder, Others
Must Not Be Taking:PARP Inhibitors
28 Participants Needed
ZEN-3694 + Talazoparib for Cancer
Lexington, Kentucky
This trial tests if combining ZEN-3694 and talazoparib can shrink advanced tumors that don't respond to standard treatments. ZEN-3694 blocks proteins that help tumors grow, and talazoparib stops cancer cells from fixing their damaged DNA, causing them to die. The study also looks at how patients' genes affect their response to this treatment. Talazoparib is a potent PARP inhibitor that has shown significant efficacy in treating advanced BRCA1 and BRCA2 mutated breast cancer.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Uncontrolled Illness, Psychiatric Illness, Pregnancy, Others
Must Not Be Taking:CYP3A4 Inhibitors, Proton-pump-inhibitors, Factor Xa Inhibitors, Factor IIa Inhibitors
88 Participants Needed
ZEN003694 + Talazoparib for Ovarian Cancer
Pittsburgh, Pennsylvania
This trial is testing a combination of two oral drugs, ZEN003694 and talazoparib, in patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer. ZEN003694 helps stop cancer cells from growing, while talazoparib blocks an enzyme that cancer cells need to repair themselves. The goal is to see how well these drugs work together in this specific group of patients.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:Female
Key Eligibility Criteria
Disqualifiers:Brain Metastases, Cardiac Disease, Others
Must Not Be Taking:CYP3A4 Inhibitors, P-gp Inhibitors, Factor Xa Inhibitors, Factor IIa Inhibitors
33 Participants Needed
Targeted Therapy + Atezolizumab for Endometrial Cancer
Pittsburgh, Pennsylvania
This trial tests drugs that target cancer cells, sometimes combined with an immune-boosting drug called atezolizumab. It focuses on patients with endometrial cancer that has returned or is persistent. The drugs are chosen based on the genetic profile of the patient's tumor to improve effectiveness.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:Female
Key Eligibility Criteria
Disqualifiers:Other Invasive Malignancies, Autoimmune Disease, Active Tuberculosis, Others
Must Not Be Taking:Immunostimulatory Agents, Immunosuppressive Medications
148 Participants Needed
Targeted Therapy for Triple Negative Breast Cancer
Indianapolis, Indiana
This is a 3-arm study stratified by plasma ctDNA. Patients with residual TNBC disease after pre-operative therapy will be assigned to 1 of 3 Arms based on plasma ctDNA positivity and genomic marker(s).
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Stage IV Disease, Active Second Malignancy, Uncontrolled Disease, Severe Allergies, Others
Must Not Be Taking:Immunosuppressants, Investigational Agents
197 Participants Needed
Know someone looking for new options?
Spread the word
Learn More About Power
We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.
Bask GillCEO at Power
Frequently Asked Questions
How much do clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.How do clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length is 12 months.How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.Do I need to be insured to participate in a medical study ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.What are the newest clinical trials ?
Most recently, we added ZEN003694 + Talazoparib for Ovarian Cancer, Talazoparib + Chemotherapy for Acute Myeloid Leukemia and ZEN-3694 + Talazoparib for Cancer to the Power online platform.Popular Searches
By Condition
By Location
Other People Viewed
By Subject
By Trial
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.